| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Novavax Inc. | NVX-CoV2373 - (Hummingbird) | COVID-19 Vaccine in Children 6 Months - 11 Years | Phase 2/3 | Ongoing | Intramuscular | COVID-19 |
| Novavax Inc. | NVX-CoV2373 - (Com-COV3) | Covid-19 vaccine in adolescents | Phase 2 | Trial Completed | Intramuscular | COVID-19 |
| Novo Nordisk A/S | AM833 (CagriSema) - (REDEFINE) | Obesity | PDUFA | Data Released | Subcutaneous | Endocrinology |
| Novo Nordisk A/S | Mim8 - (FRONTIER5) | Hemophilia A | PDUFA | Data Released | Subcutaneous | Hematology |
| Novo Nordisk A/S | Mim8 - (FRONTIER5) | Hemophilia A | PDUFA | Data Released | Subcutaneous | Hematology |
| Novo Nordisk A/S | Sogroya (somapacitan) - (REAL8) | Noonan syndrome (NS) | PDUFA | Ongoing | Subcutaneous | Genetic Disorder |
| Novo Nordisk A/S | Concizumab - (Explorer 7) | Hemophilia A | NDA Filing | Data Released | Subcutaneous | Hematology |
| Novo Nordisk A/S | Ozempic (semaglutide 1.0 mg) - (STRIDE) | Peripheral artery disease (PAD) | NDA Filing | Data Released | Subcutaneous | Cardiology |